TABLE 2.
Hospital Characteristics of Participating Centers
| Characteristic | Hospital
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | H | I | J | K | |
| No. of beds | |||||||||||
| Oncology | 435 | 109 | 100 | 24 | 600 | 27 | 185 | 125 | 56 | 26 | 22 |
| Transplant | 22 | 14 | 0 | 30 | 68 | 18 | 24 | 32 | 28 | 80 | 6 |
| Diagnostic test | PCR | EIA | CTA | PCR | EIA | PCR | CTA/PCRa | EIA | PCR | EIA | PCR |
| Surveillance definition HO-CDI (positive test from time of admission), hours | >48 | >48 | >48 | >72 | >48 | >72 | >72 | >72 | >48 | >72 | >72 |
| Second new infection (time from index episode in weeks) | 12 | NA | NA | 8 | 8 | 8 | 8 | 8 | 8 | 6 mo | 8 |
| Duration of isolation, days | |||||||||||
| No. of days (minimum) | 7 | ||||||||||
| Until resolution of symptoms | Yes (2 days) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | ||
| Minimum treatment duration | 7 | Complete | |||||||||
| Entire hospitalization | Yes | Yes | |||||||||
NOTE. CTA, cytotoxin assay; EIA, enzyme immunoassay; HO-CDI, hospital-onset Clostridium difficile infection; NA, not available; PCR, polymerase chain reaction.
a
Center with recent transition from CTA to PCR; rates were reported while CTA was in use.